The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced the successful completion of the Phase III clinical study ...

Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...

NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full ...

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel ...

SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma ...

AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class ...

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...